Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. has achieved sound development for 11 years and has grown into the ninth biggest pharmaceutical company in China’s prescription drug market. The Group is also the largest cardio-cerebral vascular prescription drug franchise by market share. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network and strong research and development capabilities.
Taking advantage of China's growing economy and ongoing healthcare reforms, we will actively seek to secure long-term growth opportunities for the Company by taking steps to expand our marketing and distribution network, enhance research and development capabilities, and optimize production capacity. We will also continually expand and enhance our portfolio of products by making use of our proven multiple channel strategy that includes acquisition and cooperation with overseas pharmaceutical companies.
Our mission is to be an international leader with fully integrated capabilities in R&D, production and sales and marketing. We will continue to be dedicated to the development and marketing of cardio-cerebral vascular drugs and to provide the best pharmaceutical products to patients.